A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
Status:
NOT_YET_RECRUITING
Trial end date:
2030-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to:
* Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD)
* Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration